

Evaluating the Health and Economic Benefits of Atypical Agents in the Treatment and Management of Psychoses

This Special Report supplement to *The American Journal of Managed Care* includes an interview with a clinical psychiatrist and 4 articles based on proceedings from a symposium held in Washington, DC on October 19 and 20, 1998.

The article, "The Emerging Role of Psychiatric Pharmacists," has been approved for continuing medical education credit by Johns Hopkins University School of Medicine and for continuing pharmacy education credit by The University of Tennessee College of Pharmacy.

All of the articles have been peer reviewed by Peter Rabins, MD, Professor of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland.

SYMPOSIUM PANEL

Chair

Anthony F. Lehman, MD, MSPH

Professor of Psychiatry
Director, Center for Mental Health Services Research
University of Maryland
Baltimore, Maryland

Panel Members

Ralph Aquila, MD

Director, Residential Community Services
St. Luke-Roosevelt Hospital Center
Assistant Clinical Professor of Psychiatry
Columbia College, Physicians and Surgeons
New York, New York

Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP, FASCP*

Director, Central Nervous System Research
Kendle International, Inc.
Cincinnati, Ohio

Walter Fitzgerald Jr., PharmD, MS, JD

Associate Professor of Pharmacy and
Pharmacoeconomics
University of Tennessee
Memphis, Tennessee

Josephine Mauskopf, PhD

Assistant Research Director
Center for Economics Research
Research Triangle Institute
Research Triangle Park, North Carolina

Jeffrey S. McCombs, PhD

Associate Professor
Department of Pharmaceutical Economics
Policy
University of Southern California School
of Pharmacy
Los Angeles, California

Douglas Noordsy, MD

Assistant Professor of Psychiatry
Dartmouth Medical School
Medical Director
Mental Health Center of Greater Manchester
Community Support Program
Manchester, New Hampshire

Sandra L. Tunis, PhD

Research Scientist
Health Outcomes Evaluation Group
Lilly Research Laboratories
Eli Lilly & Company
Indianapolis, Indiana

*At the time of the symposium, Dr. Cohen was Professor of Pharmacy, Psychiatry, and Behavioral Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma.

DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations.

■ **Ralph Aquila, MD**

Research Support From/Advisory Board Member

For:

Eli Lilly & Company

■ **Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP, FASCP**

Lecture Support From:

SmithKline Beecham

Eli Lilly & Company

Janssen

Zeneca

Wyeth Ayerst

Glaxo Wellcome

Bristol Myers Squibb

Abbott

Advisory Board Member For:

Janssen

■ **Walter Fitzgerald Jr., PharmD, MS, JD**

Research Support From:

Planet Rx

Lecture Support From:

Eli Lilly & Company

Glaxo Wellcome

DuPont Pharma

■ **Josephine Mauskopf, PhD**

Contractor For:

Eli Lilly & Company

■ **Jeffrey S. McCombs, PhD**

Research/Grant/Lecture Support From:

Eli Lilly & Company

Grant Support From:

Pharmacia & Upjohn

■ **Douglas Noordsy, MD**

Grant/Lecture Support From and

Advisory Board Member For:

Eli Lilly & Company

Lecture Support From:

Novartis

Abbott

■ **Peter Rabins, MD**

Grant/Lecture Support From:

Janssen

Lecture Support From:

Eli Lilly & Company

Pfizer

Eisai

Wyeth Ayerst

The participant listed below declares no financial arrangements or affiliations with any corporate organizations.

■ **Anthony F. Lehman, MD, MSPH**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.